Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Clene Inc. Market Cap
From what 0 stock analysts predict, the share price for Clene Inc. (CLNN) might increase by 767.99% in the next year. This is based on a 12-month average estimation for CLNN. Price targets go from $20 to $94. The majority of stock analysts believe CLNN is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedCLNN 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Clene Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CLNN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CLNN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jason Kolbert EF Hutton | Buy | $23 | Maintains | Sep 16, 2024 |
| Jason Kolbert EF Hutton | Buy | $23 | Initiates | Sep 10, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $31 | Maintains | Aug 9, 2024 |
| Sumant Kulkarni Canaccord Genuity | Buy | $94 | Reiterates | Aug 6, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Jun 21, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Jun 18, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | May 28, 2024 |
| Bruce Jackson Benchmark | Buy | $5 | Reiterates | May 23, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | May 8, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Apr 17, 2024 |
| Bruce Jackson Benchmark | Buy | $5 | Reiterates | Mar 20, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Mar 13, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Maintains | Mar 11, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Feb 22, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Dec 21, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Sep 21, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Aug 29, 2023 |
| Jonathan Aschoff Roth MKM | Buy | $10 | Reiterates | Aug 29, 2023 |
| Charles Duncan Cantor Fitzgerald | Overweight | $4 | Reiterates | Aug 16, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Aug 14, 2023 |
When did it IPO
N/A
Staff Count
82
Country
United States
Sector/Industry
Consumer Defensive/Packaged Foods
CEO
Mr. Robert Etherington MBA
Market Cap
$37.7M
In 2023, CLNN generated $654,000 in revenue, which was a increase of 38.27% from the previous year. This can be seen as a signal that CLNN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings.
Thu, 29 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - The consensus price target hints at an 873.5% upside potential for Clene (CLNN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tue, 13 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - The mean of analysts' price targets for Clene (CLNN) points to a 976.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SALT LAKE CITY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its second quarter 2024 financial results and provided recent updates on its CNM-Au8® programs.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - LOS ANGELES, Aug. 08, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
Wed, 07 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Clene Inc. (CLNN) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.60. This compares to loss of $2.40 per share a year ago.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
